Renal Biomarkers Market Report 2026

The renal biomarkers market size has grown strongly in recent years. It will grow from $1.37 billion in 2025 to $1.49 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increased use of creatinine and urea testing, expansion of diagnostic laboratory infrastructure, growing awareness of early kidney injury detection, improvements in immunoassay technologies.

The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to $2.04 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for predictive renal diagnostics, expansion of biomarker-based clinical research, growing integration of AI in biomarker analysis, increasing focus on personalized nephrology care. Major trends in the forecast period include increasing adoption of novel kidney injury biomarkers, rising use of multi-biomarker panels in diagnostics, growing demand for early detection of kidney damage, expansion of non-invasive urine-based testing, enhanced focus on disease progression monitoring.

The increasing burden of chronic kidney disease (CKD) is anticipated to drive the growth of the renal biomarkers market in the coming years. Chronic kidney disease is a long-term medical condition marked by a gradual loss of kidney function, which impairs the body’s ability to remove waste products, regulate fluid levels, and maintain essential electrolyte balance. The rising prevalence of CKD is largely attributed to aging populations, the growing incidence of diabetes and hypertension, and genetic risk factors, all of which contribute to elevated rates of kidney-related complications and mortality. Renal biomarkers are essential in clinical settings as they support early diagnosis, enable monitoring of disease progression, and facilitate timely therapeutic interventions to help prevent progression to kidney failure. For example, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease accounted for 1.1% of the total disease burden in Australia, with age-adjusted data indicating that males experienced 1.3 times the disease burden observed in females. Therefore, the growing burden of chronic kidney disease is fueling the growth of the renal biomarkers market.

Major companies operating in the renal biomarkers market are increasingly engaging in advanced collaborations with research institutions and AI-driven biotechnology firms to enhance biomarker discovery, improve patient stratification, and strengthen precision diagnostic capabilities. These strategic partnerships are focused on accelerating the discovery and validation of novel biomarkers that enable earlier disease detection, more accurate risk assessment, and personalized treatment strategies for kidney disorders. For instance, in November 2024, MultiOmic Health, a UK-based AI-powered drug discovery company, identified new patient endotypes and proprietary biomarkers for diabetic kidney disease (DKD) through a research collaboration with the Northern Care Alliance NHS Foundation Trust. These biomarkers support precise patient segmentation and aid in the development of targeted diagnostic tools and therapies, contributing to improved clinical decision-making and patient outcomes in kidney care.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed amount. This notable acquisition of a Chinese biotechnology firm by a multinational company underscores China’s growing role in the global renal therapeutics market and aligns with Novartis’ strategic focus on advancing innovative treatments for kidney diseases. SanReno Therapeutics is a China-based biopharmaceutical company specializing in therapies for renal disorders.

Major companies operating in the renal biomarkers market are Abbott Laboratories, BioPorto Diagnostics A S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Sphingotec GmbH, Bio Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Alere Inc., Bio Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R And D Systems Inc., Roche Diagnostics International Ltd, Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

North America was the largest region in the renal biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renal biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the renal biomarkers market by increasing the cost of imported reagents, assay kits, laboratory instruments, and analytical equipment used in ELISA, CLIA, and mass spectrometry testing. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported consumables and high-end diagnostic platforms, while Asia-Pacific faces pricing pressure on exported diagnostic kits. These tariffs are elevating testing costs and slowing procurement of advanced diagnostic tools. However, they are also encouraging local production of assay kits, regional reagent manufacturing, and increased investment in domestic diagnostic innovation.

The renal biomarkers market research report is one of a series of new reports that provides renal biomarkers market statistics, including renal biomarkers industry global market size, regional shares, competitors with a renal biomarkers market share, detailed renal biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarkers industry. This renal biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Renal biomarkers refer to proteins, lipids, genes, metabolites, proteomic patterns, or cells detected through urinalysis that are used to assess the kidney’s glomerular filtration rate, a reduction of which indicates kidney damage. These biomarkers help evaluate the nature and severity of kidney injury.

The main types of renal biomarkers include functional biomarkers, upregulated proteins, and other biomarker categories. Functional biomarkers are indicators that enable the diagnosis of kidney injury in individuals with normal kidney function, as well as in patients with chronic kidney disease, where the same injury would result in a marked decline in functional markers such as creatinine. The diagnostic techniques used include enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LC-MS). These biomarkers are applied in diagnosis, disease progression monitoring, and research and homecare settings, and are used by hospitals, diagnostic laboratories, and other end users.

The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.